Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00606294 · ClinicalTrials.gov registry record · NA
Using Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission Tomography To Detect Hypoxia in Head and Neck Cancer Patients
A NA study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 216
- Enrollment target
NCT00606294: Completed NA study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00606294 is a NA study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 216 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00606294, a NA study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 216 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate low oxygen areas called hypoxia within tumors. These low oxygen areas are thought to be the reason why tumors are more resistant to chemotherapy and radiation treatment. An imaging technique using a hypoxia tracer called fluoromisonidazole (FMISO) can detect low oxygen areas within a tumor. This imaging technique, called a PET scan, uses positively charged particles to detect slight changes in the body's biochemistry and metabolism. FMISO PET scans have been performed in patients with head and neck cancer and have shown the ability to detect low oxygen areas within tumors.
Interventions
- DEVICE MRI
- RADIATION fluorine-18-labeled fluoro-misonidazole (18F-FMISO)
- DEVICE 18F-FMISO PET scan
- DEVICE FDG PET/CT scan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 216 participants |
| Start Date | 2004-06 |
| Est. Completion | 2023-06-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00606294
The ClinicalTrials.gov registry entry for NCT00606294 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 216 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which MRI is the first listed.
NCT00606294 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00606294 about?
NCT00606294 is a clinical study titled "Using Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission Tomography To Detect Hypoxia in Head and Neck Cancer Patients". The main purpose of this study is to evaluate low oxygen areas called hypoxia within tumors. These low oxygen areas are thought to be the reason why tumors are more resistant to chemotherapy and radiation treatment. An imaging technique using a hypoxia tracer called fluoromisonidazole (FMISO) can d...
What is the current status of trial NCT00606294?
This trial is currently completed. It is a NA study. The enrollment target is 216 participants. The study started on 2004-06. Estimated completion is 2023-06-09.
What interventions are being tested in trial NCT00606294?
The interventions under investigation include: MRI (DEVICE), fluorine-18-labeled fluoro-misonidazole (18F-FMISO) (RADIATION), 18F-FMISO PET scan (DEVICE), FDG PET/CT scan (DEVICE).
Who is sponsoring clinical trial NCT00606294?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.